Oklo Gets Final DOE Operational Clearance For Groves-1 Reactor – Retail Eyes 85% Upside By 2026-End

• Groves-1 will help Oklo test reactor equipment, improve operating procedures, and train personnel for future projects.
• Experience gained from operating Groves-1 will support Oklo’s planned Groves-2 Forge facility, the company said
• Groves-2 will initially focus on lutetium-177, a radioactive isotope used in targeted cancer treatments.

Shares of Oklo (OKLO) jumped more than 6% on Wednesday after the U.S. Department of Energy (DOE) cleared its Groves-1 nuclear test reactor for unrestricted operations, a key step in the company’s plans to develop medical isotopes for cancer treatments.

The DOE cleared the final operational restriction on Groves-1, allowing the reactor to enter its research, testing and training phase.

Read Next

RGTI Stock Sees Its Price-Target Cut By Up To 52% Despite Quantum Fidelity Gains — Company Sets Sights On 1,000-Qubit System

Harshita Tyagi

Groves-1 To Support Aurora Operations

The Texas-based facility will help Oklo test reactor equipment, improve operating procedures and train personnel for future projects, including its Aurora fast-fission nuclear power plants. The reactors are designed to supply electricity to AI data centers and industrial facilities.

In August, Groves-1 became the first reactor under the DOE's Reactor Pilot Program to achieve criticality on private land, generating a controlled, self-sustaining nuclear chain reaction less than a year after construction began.

Focus On Cancer Treatment Isotope

Experience gained from operating Groves-1 will support Oklo’s planned Groves-2 Forge facility, the company said. Unlike Groves-1, which focuses on testing and training, Groves-2 will be used for medical isotope production, processing, packaging and transportation.

The facility will initially focus on lutetium-177, a radioactive isotope used in targeted cancer treatments that deliver radiation directly to cancer cells.

Retail Bulls Eye $50 By Year-End

Retail sentiment surrounding OKLO remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.

One user expects the stock to climb to at least $50 by the end of the year. This represents about 85% upside from current levels.

OKLO shares have been under heavy selling pressure this year, slumping more than 67%.

Also read: Lithium Americas Raises Flagship Project Cost Estimate By $900M – CEO Says Phase 1 Completion Targeted For Late 2027

For updates and corrections, email newsroom[at]stocktwits[dot]com.